Skip to main content
Clinical Trials/NCT03270098
NCT03270098CompletedNot Applicable

Improving Cognition Via Exercise in Schizophrenia

Icahn School of Medicine at Mount Sinai4 sites in 1 country104 target enrollmentStarted: April 26, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
104
Locations
4
Primary Endpoint
Change in VO2Max

Study Overview

Brief Summary

People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. Also, people with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime. The goal of the proposed study is to examine the impact of remote exercise training on cognition, suicide risk, daily functioning, and biomarkers of cognitive change and suicidality in people with schizophrenia.

Detailed Description

The goal of the proposed study is to examine the impact of remote exercise training on cognitive functioning in people with schizophrenia. People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functional outcome and disability, thus representing an important public health concern and a target for interventions. At present, available treatments offer only minimal to limited benefits to ameliorate these deficits. Extensive animal and human research literatures converge in supporting the positive influence of aerobic exercise training on cognitive functioning. Preliminary data indicate that aerobic exercise training is effective in improving cognitive functioning in people with schizophrenia. However, previous studies employed small samples, focused on a single or limited range of cognitive domains, and/or collected insufficient information on daily functioning or putative biomarkers underlying cognitive change. Supported by supplement funding from NIMH, the goal of the proposed study is also to explore the impact of remote exercise training on suicide risk in individuals with schizophrenia. People with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime, and an estimated 5-10% actually being successful in completing suicide. This highly elevated risk represents a serious public health concern and an important target for interventions. However, available treatments offer only minimal to limited benefits to ameliorate this risk. Extensive animal and human research literatures converge in supporting the positive influence of AE training on a number of predictors of suicide risk including depressed mood, sleep difficulties, and poor cognition. Yet, at present there are no studies directly examining the impact of AE on suicide risk in this population.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 55 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •A DSM-V diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder.
  • •Age 18-55 years.
  • •Taking antipsychotic medication for at least 8 weeks and on current doses for 4 weeks, and/or injectable depot antipsychotics with no change in the last 3 months.
  • •Capacity to understand all the potential risks and benefits of the study.
  • •Medically cleared by a physician to take part in VO2max tests and aerobic exercise training or stretching-and-toning exercise training.

Exclusion Criteria

  • •A DSM-V diagnosis of alcohol/substance abuse (except nicotine) within the last month or a diagnosis of alcohol/substance dependence (except nicotine) within the last 6 months
  • •Initiation of anti-depressants, mood stabilizers, or other medications known to impact cognition in previous 4 weeks or any change in doses during this period.
  • •History of seizures/head trauma with loss of consciousness (>10 minutes) resulting in cognitive sequelae.
  • •Significant clinical abnormalities in physical examination, lab assessments, or ECG.
  • •Neurological/medical conditions that could interfere with study participation (e.g., unstable cardiac disease, stuttering).
  • •Body Mass Index (BMI) ≥
  • •Untreated hyper- or hypothyroidism.
  • •Being pregnant or nursing.
  • •Serious homicidal/suicidal risk (past 6 months).
  • •"Moderate" or more severe conceptual disorganization (PANSS≥4).
  • •Poor English reading ability (WTAR<7).
  • •Participation in a study with cognitive assessment in the past 3 months.
  • •Serious homicidal risk (past 6 months)

Arms & Interventions

Aerobic Exercise

Experimental

Using trainer-led video calls with traditional callisthenic body movements (e.g., jumping jacks, burpees, etc.)

Intervention: Aerobic Exercise (Behavioral)

Stretching and Toning Exercise

Active Comparator

Using trainer-led video calls with stretching and toning exercises.

Intervention: Stretching and Toning Exercise (Behavioral)

Outcomes

Primary Outcomes

Change in VO2Max

Time Frame: Baseline and 12 weeks

VO2Max (maximal oxygen consumption) is an index of the ability to consume oxygen and is a key indicator of aerobic fitness. Change in the VO2Max at 12 weeks as compared to baseline.

Change in the MATRICS Consensus Cognitive Battery (MCCB)

Time Frame: Baseline and 12 weeks

The MCCB is a standardized battery designed to measure cognitive functioning in people with schizophrenia. The MCCB is represented as a composite T score. Change in the MCCB at 12 weeks as compared to baseline.

Secondary Outcomes

  • Serum BDNF(Baseline and 12 weeks)
  • Change in Columbia Suicide Severity Rating Scale (C-SSRS)(Baseline and 12 weeks)
  • Change in the Specific Levels of Functioning Scale (SLOF)(Baseline and 12 weeks)
  • Change in the UCSD Performance-based Skills Assessment (UPSA)(Baseline and 12 weeks)
  • Change in the Schizophrenia Cognition Rating Scale (SCoRS)(Baseline and 12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

David Kimhy

Associate Professor, Psychiatry

Icahn School of Medicine at Mount Sinai

Study Sites (4)

Loading locations...

Similar Trials